Back

Cell Reports

25 training papers 2019-06-25 – 2026-03-07

Top medRxiv preprints most likely to be published in this journal, ranked by match strength.

1
Glial Maturation and Immune Landscape Dynamics in MN1::PATZ1 Fusion-Positive CNS Tumor Recurrence.
2026-02-24 oncology 10.64898/2026.02.19.26345901
#1 (3.3%)
Show abstract

BackgroundPATZ1 fusion-positive central nervous system (CNS) tumors frequently harbor MN1::PATZ1 fusions as driver mutations, provisionally classified as a rare DNA methylation class of low-grade neuroepithelial tumors. Radiographically, they resemble pilocytic astrocytomas with tumor and cystic components, but their supratentorial cortex location and higher recurrence rates are distinguishing features. An intermediate clinical course, despite focal high-grade histopathology, underscores the nee...

2
Extracellular Vesicle-Associated Syndecan-1 Differentiates Pediatric Brain Tumor Patients with High-Grade from Low-Grade Pilocytic Astrocytoma
2026-01-27 oncology 10.64898/2026.01.22.26344286
#1 (2.9%)
Show abstract

Reliable non-invasive biomarkers for tumor grading and disease monitoring in pediatric brain tumors are an unmet clinical need. Circulating extracellular vesicles (EVs) carrying molecular cargo reflective of tumor biology, offer promise as liquid biopsy tools. We have previously discovered EV-associated Syndecan-1 (SDC1) to be overexpressed in malignant brain tumors, but its value as a biomarker in pediatric disease remains unclear. In this study, plasma EVs were isolated from pediatric brain tu...

3
LncRNA CDKN2B-AS1 C-Allele: A High-Risk Genetic Determinant in Cancer Susceptibility and Progression Impacting Immune Cell Modulation Dynamics with Therapeutic Implications
2026-01-08 oncology 10.64898/2026.01.04.25341444
#1 (2.9%)
Show abstract

Examining LncRNA-driven cancer biology, our study represents the first comprehensive investigation of the LncRNA CDKN2B-AS1 across multiple cancer types, revealing its genetic basis for cancer susceptibility, and associations with thromboembolic risks and immunological dynamics. Stratification across hematological and non-hematological cancers revealed predominant prevalence rates of the CDKN2B-AS1 C-allele, notably higher in solid tumor malignancies, peaking at 86.8% in colorectal carcinoma (CR...

4
Platelet transcriptomic signatures in pediatric brain tumors distinguish cancer from cancer-free control
2025-12-17 oncology 10.64898/2025.12.17.25341356
#1 (2.9%)
Show abstract

BackgroundMalignant pediatric brain tumors remain the leading cause of cancer-related mortality in children. Current diagnostics rely on imaging and invasive biopsy, which may not capture tumor heterogeneity. Liquid biopsy-based biomarkers such as tumor-educated platelets have shown diagnostic value in adult cancers, but their utility in pediatric brain tumors has not been investigated. MethodsWe analyzed platelet transcriptomes of 73 blood samples from 23 pediatric brain tumor patients, classi...

5
Viral-based individualized neoantigen vaccine as adjuvant treatment in resected head and neck squamous cell carcinoma: immunogenicity and efficacy from a randomized Phase I trial
2026-01-06 oncology 10.64898/2026.01.06.25342687
#1 (2.8%)
Show abstract

In approximately one third of patients, resected head and neck squamous cell carcinoma will recur. We postulated that the induction of tumor neoantigen-specific T cell responses could prevent relapse. To this end, we developed TG4050, an individualized neoantigen therapeutic vaccine encoding up to 30 patient-specific predicted tumor neoantigens delivered by a Modified Vaccinia Ankara virus viral vector. We tested TG4050 as single agent in a randomized phase I trial. We found that of 16 evaluable...

6
Multimodal single-cell and spatial profiling reveals altered T cell-mediated immunity and B-cell follicular architecture in non-metastatic lymph nodes of patients with aggressive non-small cell lung cancer
2026-01-18 oncology 10.64898/2026.01.12.25343268
Top 0.1% (2.1%)
Show abstract

Regional lymph nodes (LNs) in the thoracic cavity serve as essential immunological hubs that coordinate humoral and cell-mediated responses against the development and progression of non-small cell lung cancer (NSCLC). To investigate immune dysregulation in the non-metastatic regional LNs of patients with aggressive NSCLC, we performed multimodal profiling on 36 LNs from 11 patients undergoing curative-intent resection including CITE-seq, scRNA-seq, and Imaging Mass Cytometry (IMC). Regional N1 ...

7
Remodelling of the gut virome after long-term fasting
2025-12-22 nutrition 10.64898/2025.12.19.25342476
Top 0.1% (2.0%)
Show abstract

BackgroundLong-term fasting is a promising strategy for improving human health and reducing cardiometabolic risk. Emerging evidence suggests that the gut microbiome may mediate many of these benefits, but the role of its viral component, dominated by bacteriophages, remains poorly understood. MethodsUsing shotgun metagenomic data from a single-arm, monocentric fasting intervention, this study profiled the gut virome (n=89 individuals, n=241 samples) before and after 9.8 days of fasting ([~]250 ...

8
Functional Profiling of DNA Repair Pathways in Lung Cancer Patients Uncovers Radiotherapy-Induced and Cancer-Associated Alterations in Oxidative Lesion Repair.
2026-01-13 oncology 10.64898/2026.01.12.26343971
Top 0.2% (2.0%)
Show abstract

DNA repair capacity (DRC), particularly at the pathway level, varies among individuals. While previous studies explored DRC in relation to environmental exposures and cancer risk, few measured DRC in patient-focused cohorts and were focused on one or two repair pathways only. We comprehensively profiled DRC for all the major repair pathways and DNA lesions in 100 lung cancer patients undergoing radiotherapy (RT) using advanced Fluorescence Multiplex based Host Cell Reactivation assays in blood c...

9
Genomic characterization of therapy-associated polyposis reveals an alkylating mutational signature from prior treatment
2026-02-22 oncology 10.64898/2026.02.12.25340205
Top 0.2% (1.9%)
Show abstract

Gastrointestinal (GI) polyposis is a major risk factor for colorectal cancer (CRC) and a defining feature of hereditary polyposis syndromes such as familial adenomatous polyposis (FAP). Therapy-associated polyposis (TAP), however, is a rare and incompletely characterized condition that develops decades after treatment for childhood or young adult cancers (CYAC), most often following abdominopelvic radiation or exposure to alkylating agents. As long-term CYAC survival improves, the burden of late...

10
Targeting Multiple Immune Checkpoints with a Single Therapy: Implications for Treating Central Nervous System Tumors
2026-02-14 oncology 10.64898/2026.02.10.26345679
Top 0.3% (1.9%)
Show abstract

BackgroundImmune checkpoint inhibition has transformed cancer therapy; however, many patients fail to respond to single-agent blockade, and combination strategies are often limited by toxicity. Central nervous system tumors exploit multiple immunosuppressive pathways, including the CD200 and PD-1/PD-L1 axis to evade anti-tumor immunity and support tumor aggressiveness. MethodsWe investigated ARL200, a peptide ligand targeting the CD200 activation receptor (CD200AR) using in vitro immune assays,...

11
Mapping the specificity of H3N2 strain-specific and cross-reactive human neutralizing antibodies elicited by the 2025-2026 influenza vaccine
2026-02-22 infectious diseases 10.64898/2026.02.20.26346746
Top 0.3% (1.9%)
Show abstract

An H3N2 variant, named subclade K, continues to circulate widely during the 2025-2026 influenza season. This virus possesses a hemagglutinin (HA) protein that has eleven substitutions relative to the HA of the Northern Hemisphere 2025-2026 H3N2 vaccine strain. Many of these substitutions are in epitopes in well-characterized HA antigenic sites. Despite this, interim vaccine effectiveness studies indicate that the 2025-2026 influenza vaccine provides moderate protection against H3N2 subclade K in...

12
ICI-induced Granulomatous Sialadenitis is Responsive to Prednisone
2026-01-26 allergy and immunology 10.64898/2026.01.21.26344113
Top 0.3% (1.9%)
Show abstract

Immune checkpoint inhibitors (ICIs) have transformed cancer treatment but commonly cause immune-related adverse events (irAEs), whether administered as monotherapy or in combination with other oncological agents. We present the first reported case of ICI-induced granulomatous sialadenitis in a male patient in his mid-fifties with BRAF-V600E-mutated papillary thyroid carcinoma who received sequential treatment with BRAF/MEK inhibitors followed by pembrolizumab. The patient experienced acute-onset...

13
TRAF1 S146 is constitutively phosphorylated in primary CLL cells by PKN1/2
2026-02-17 oncology 10.64898/2026.02.11.26346036
Top 0.3% (1.8%)
Show abstract

TRAF1 is a pro-survival signaling adaptor that contributes to NF-{kappa}B activation downstream of a subset of TNFR superfamily members. TRAF1 is overexpressed in many cancers of mature B cells, including chronic lymphocytic leukemia (CLL). Previous studies have established that TRAF1 S146 is a target of phosphorylation by the kinase PKN1 and that PKN1 is required to prevent cellular inhibitor of apoptosis protein (cIAP)-dependent degradation of TRAF1 in the CD40 signaling complex. The kinase in...

14
Genomic profiling implicates candidate genes and mutagenic pathways driving lung cancer recurrence
2026-01-01 oncology 10.64898/2025.12.24.25342926
Top 0.3% (1.6%)
Show abstract

Lung cancer remains the leading cause of cancer-related deaths worldwide, with tumor recurrence a major contributor to its high mortality. The genetic and molecular mechanisms of recurrence remain poorly understood. Using whole-exome sequencing of 155 primary non-small cell lung cancers, we studied the mutational landscape and driver alterations associated with recurrence. Primary tumors that developed recurrence had higher mutational burden, including hypermutated tumors explained by mutations ...

15
Uncovering the potential of circulating tumor DNA for pediatric precision oncology, the INFORM experience
2026-01-22 oncology 10.64898/2026.01.19.26344140
Top 0.3% (1.6%)
Show abstract

Pediatric solid high-risk malignancies mostly lack established molecular biomarkers for early detection, minimal residual disease assessment, or treatment monitoring. Challenges include small patient numbers, limited sample volumes, low tumor mutational burden, and few recurrent alterations. Within the prospective multicenter pediatric precision oncology program INFORM, we collected liquid biopsies from 130 pediatric patients and optimized cfDNA isolation and analysis. Whole-genome, whole-exome,...

16
Peptidomic profiling reveals extracellular matrix remodeling signatures discriminative of multiple myeloma
2026-01-12 oncology 10.64898/2026.01.08.26343675
Top 0.4% (1.5%)
Show abstract

Multiple myeloma (MM) evolves from monoclonal gammopathy of undetermined significance (MGUS) and smoldering MM (SMM) with annual progression rates of 1% and 10%, respectively. Current risk models dont fully capture the underlying dynamic molecular processes. We hypothesized that urinary peptides reflect disease-specific microenvironmental alterations in plasma cell dyscrasias. To test this hypothesis, capillary electrophoresis-mass spectrometry CE-MS was applied to profile the urinary peptidome ...

17
Effects of Arylsulfatase B and Pembrolizumab in Combination on Progression of Metastatic Melanoma in the B16F10 Syngeneic Mouse Model
2026-01-02 oncology 10.64898/2026.01.02.25343295
Top 0.4% (1.5%)
Show abstract

In this report, experiments were performed to assess how Arylsulfatase B (ARSB; N-acetylgalactosamine-4-sulfatase) treatment might interact with Pembrolizumab and improve therapeutic responses in melanoma. ARSB acts to remove 4-sulfate groups from chondroitin 4-sulfate (C4S; chondroitin sulfate A; CSA). ARSB is required for the degradation of C4S, identified as an oncofetal, tumor-agnostic antigen. Previous reports showed that in syngeneic B16F10 mouse melanomas, ARSB inhibited progression of su...

18
Whole Genome Sequencing Informed Patient Personalized Measurable Residual Disease Assays for Acute Myeloid Leukemia
2026-01-24 oncology 10.64898/2026.01.22.26343677
Top 0.4% (1.5%)
Show abstract

Post-treatment measurable residual disease (MRD) in acute myeloid leukemia (AML) patients is associated with adverse clinical outcomes. Validated molecular methods for AML MRD are preferable to flow cytometry assays but are not available for all patients. The limit of detection (LOD) of next-generation sequencing (NGS) assays for single nucleotide variants is restricted by technical error rates. Structural alterations are common genetic features of AML, but MRD approaches for detecting this clas...

19
Antibodies elicited by the 2025-2026 influenza vaccine in humans
2026-01-06 infectious diseases 10.64898/2026.01.05.26343449
Top 0.5% (1.4%)
Show abstract

A new H3N2 variant (named subclade K) possesses several key hemagglutinin substitutions and is circulating widely during the 2025-2026 influenza season. In this report, we completed experiments to determine if the 2025-2026 seasonal influenza vaccine elicits antibodies in humans that recognize this variant. We find that H3N2 subclade K viruses are antigenically advanced; however, the 2025-2026 seasonal influenza vaccine elicited antibodies in many individuals that efficiently recognized these vi...

20
Hypomethylation on cfDNA within transposable elements can predict ovarian malignancy in women with adnexal masses
2026-01-16 oncology 10.64898/2026.01.14.26344128
Top 0.6% (1.4%)
Show abstract

ObjectiveTumor transformation is accompanied by widespread methylation changes, in the form of cytosine modifications, in transposable elements (TEs). The purpose of this study was to investigate whether changes in methylation and hydroxymethylation in the form of 5mC and 5hmC within transposable elements in circulating cell-free DNA (cfDNA) can serve as predictive markers of ovarian malignancy. MethodsHealthy women as well as women undergoing surgery for various benign, borderline, or malignan...